Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Riot Platforms Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Riot Platforms Inc trades at $21.07 (market cap $8.01B). The key difference: Riot Platforms Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | RIOT | |
|---|---|---|
Market Cap | $4.49B | $8.01B |
Sector | Health | Technology |
52-Week High | $28.06 | $28.67 |
52-Week Low | $20.06 | $11.03 |
Enterprise Value | $3.69B | $8.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
RIOT trades at $22.87, up 3.44% today, but technical indicators signal a bearish trend with resistance at $24. The company reported a net loss of $663.18 million in 2025 with negative cash flow from operations, though revenue reached $647.44 million. Recent news highlights volatility tied to Bitcoin price swings and a strategic pivot toward high-performance computing data centers, including a partnership with Terrestrial Energy for nuclear-powered facilities.
Wall Street analysts remain overwhelmingly bullish with a 94% buy rating and $27.83 consensus price target, but high valuation multiples and persistent losses pose significant risks. Investment appeal hinges on successful execution of the AI data center strategy amid competitive and regulatory pressures in the energy-intensive mining sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
